In order to establish the requisite landing zone for thoracic endovascular aortic repair (TEVAR), it is often necessary to cover the orifice of the left subclavian artery (LSA) with an endovascular graft. This procedure has been performed in up to 68.0% of repairs. [1] [2] [3] [4] In such situations, retrograde flow through the LSA may cause a type II endoleak, aneurysmal sac expansion or rupture. 1, [5] [6] [7] [8] [9] As such, LSA occlusion is a procedure that is widely established to be necessary in TEVAR.
Embolization of the proximal portion of the LSA from the LSA orifice to the vertebral artery origin has been traditionally performed by conventional coil embolization (CCE). CCE, while often successful, can occasionally be problematic because of coil misplacement and the need for multiple coils (Fig. 1) . 9 In the last decade, Amplatzer Vascular Plug II (AVP II) (St. Jude medical, St. Paul, MN) has been commercially available in Japan. AVP II has three multi-layered nitinol mesh lobes for rapid embolization of the vessel and has since been used for embolization of the internal iliac artery during endovascular aortic repair for abdominal aortic aneurysms. 10 The effectiveness of AVP II embolization for the LSA in selected cases has also been reported in the literature. 5, 11, 12 However, AVP II application for the LSA is technically difficult because the proximal portion of the LSA from the LSA orifice to the vertebral artery origin is not long enough for the AVP II place- 
MATERIALS AND METHODS
This present study was approved by the institutional review board of the authors' institution (1704A012). We retrospectively reviewed the records of 30 patients from June 2013 to March 2016. Patient demographics and pathologies are summarized in Table 1 .
Embolization procedures
In the CAE group, 5 or 6-French guiding sheath introducer (Destination; Terumo Medical Corporation, Tokyo, Japan) was inserted by the transaxillary approach with surgical cut-down or percutaneous transbrachial approach. The inner diameter of the LSA was measured by contrast enhanced computed tomography (CT) in advance. The AVP II that was approximately 30-50% larger than the maximum diameter of the LSA was selected. When the AVP II reached the proximal portion of the LSA, the fi rst lobe of the AVP II was deployed. Then, the introducer sheath was used to compress the fi rst lobe. The second and third lobes were subsequently compressed in the same manner (Fig. 2 ). In the CCE group, coaxial intubation of the LSA was performed with a microcatheter (Progreat β3; Terumo Medical Corporation, Tokyo, Japan) using a percutaneous transbrachial approach. LSA occlusion was achieved with detachable microcoils (Interlock; Boston Scientifi c, Natic, MA) with the choice of the appropriate coil size based on the diameter of the LSA. Finally, complete LSA occlusion was confi rmed by retrograde digital subtraction angiography. The stent-graft deployment was done prior or subsequent to the LSA embolization.
Evaluation of treatment and patient follow-up
Technical success (defined as successful compression and placement of AVP II without sealing the LSA orifi ce) and complication rate of LSA embolization and the TEVAR procedure were evaluated. The amount of embolic material in the LSA by both methods was compared. To evaluate the device length of the AVP II by compression, we calculated the compression ratio by comparing the compressed AVP II length in the LSA to uncompressed AVP II length in the ex-vivo tube model ( in the ex-vivo tube model. When an AVP II of device size of 16mm was deployed using the uncompressed conventional technique in the ex-vivo tube model whose inner diameter were 11 and 12 mm, while the length of deployed AVP II were 52 and 49 mm, respectively. In cases of AVP II 14 mm and tube models of 9, 10, and 11 mm, the length of deployed AVP II were 50, 46, and 42 mm, respectively. In AVP II 12 mm and tube models 9, 8 mm, the lengths of deployed AVP II were 36, 42 mm, respectively. In AVP II 10 mm, tube model 8 mm, the length of deployed AVP II was 29 mm (unpublished data). The costs of devices used for embolization, according to redemption prices determined in the health insurance programs in Japan, were also compared between the two groups.
The dynamic contrast enhanced CT was performed at 1 week, 6 and 12 months after the TEVAR procedure. Clinical success was defined as the absence of type II endoleak from the LSA on follow-up CT. Patient demographics, treatment modalities and outcomes were compared (Fig. 4) .
A comparison of continuous variables was made using the Mann-Whitney U test for independent variables, while categorical variables were compared using Fisher's exact test with the IBM SPSS Statistics version 24. Differences were considered significant if the twotailed P value was < .05.
RESULTS

Procedures and perioperative period
The CCE was performed in 6 patients, while the CAE was performed in 24 patients. The patients in the CAE group, aged 31-90 years (mean 76.2), consisted of 22 males (91.7%) and 2 females. The patients in the CCE group, aged 69-88 (mean 78.7), consisted of 5 males and 1 female. Both groups had similar demographics and cardiovascular risk factors, with the exception of a greater rate of chronic kidney disease in the CAE group (CAE: 42%, CCE: 0%, P = .05). Selective revascularization was performed in 3 patients (50.0%) in the CCE group and 20 patients in the CAE group (83.3%).
Technical success of LSA embolization was achieved at 100 % in both groups (Table 2 ). In the CAE group, the AVP II of the device size 10, 12, 14 and 16mm were used for embolization of the LSA with an inner diameter of 8-12 (mean 10.0 ± 0.9) mm. The length of compressed AVP II was 15-24 (mean 19.0 ± 3.6) mm. The length of the proximal portion of the LSA from the LSA orifice to the vertebral artery origin was 24-62 (mean 41.7 ± 8.9) mm in the CAE group and the length of uncompressed AVP II was 29-52 (mean 45.9 ± 4.9) in the tube model. In seventeen patients of the CAE group (70.8%), the length of uncompressed AVP II in the tube model was equal to or larger than that of the proximal portion of the LSA from the LSA orifice to the vertebral artery origin in the CAE group. The mean compression ratio of AVP II was 58.6 ± 5.9 %. In the CAE group, emergency TEVAR was applied for ruptured thoracic aortic aneurysm. No major complication such as a stroke or shower embolism was noticed in all but one patient. One patient died from a re-rupture of an aneurysmal sac due to type 1b endoleak seven days after the TEVAR. Although a larger-sized introducer was used in CAE, there was no significant difference in any access route-related complications in both groups.
The number of embolization material in the CAE group and CCE group were one and 10.2 ± 2.7, respectively (P < .01). The costs incurred from embolization material were lower in the CAE group (CAE: 129,000 JPY, CCE: 639,600 ± 140,060 JPY, P < .01).
Follow-up period
The mean follow-up period was 381 days (range, 7-768 days) in the CAE group, and 942 days (range, 714-1116 days) in the CCE group. Although type II endoleak was detected in five CAEs and three CCEs, no LSA-related endoleak was observed. Migration of any embolic material was not found. No ischemic symptoms of the left arm due to the LSA embolization were recorded throughout the follow-up period. Aneurysmal sac enlargement of more than 5 mm in diameter was not observed in any case within the follow-up period. DISCUSSION TEVAR has become increasingly popular in the treatment of aneurysms and type B aortic dissections. [13] [14] [15] [16] [17] When the proximal end of the aneurysmal sac or entry tear is close to the orifice of LSA, it is often necessary to cover the LSA orifice to establish this required landing zone for stent-grafting. Patency of the proximal portion of the LSA may cause a type II endoleak. Type II endoleaks may resolve spontaneously, but persistent pressurization of the aneurysmal sac places the patient at risk of sac rupture. 5 Consequently, the presence of a type II endoleak, particularly in the setting of aneurysm sac enlargement, is an indicator of a poor clinical outcome and requires repair. 9 LSA occlusion, with or without surgical arch debranching, is needed to prevent type II endoleak. Conventional occlusion methods of the proximal portion of the LSA to deal with type II endoleak include surgical ligation or catheter-directed embolization with metal coils or glue. 3 AVP II prosthesis, which is an excellent vessel occlusion device for medium to large vessels with high flow, consists of nitinol mesh with varying numbers of wires (144 to 360) with different designs (one to three layers of wires). It has three lobes of equal diameter without the presence of tissue inside. Meyer et al. reported AVP II to be a safe and easy-to-use instrument demonstrating rapid permanent occlusion of the left-subclavian back flow type II endoleak. 18 However, AVP II embolization requires a specific length of arterial segment because three lobes of AVP II are deployed by their extension in the arterial lumen. In addition, the length of the proximal portion of the LSA from the LSA orifice to the vertebral artery origin of the LSA is often too short for AVP II placement with the uncompressed conventional technique. In our study, the length of the proximal potion of the LSA was equal to or shorter than AVP II length with the conventional procedure in the tube model in seventeen patients of the CAE group (70.8%). Even in such situations, we could successfully embolize the proximal portion of the LSA using compressed AVP II.
Concerning the application of compressed AVP II for the embolization of LSA, there are several risks to consider. The lobe deformity of AVP II by compression might cause insufficient occlusion. In addition, the compression may cause distal embolization from atherothrombotic debris because of abrasion of the surface of the artery from the mesh lobe during the procedure. To resolve these risks, we have performed animal experiments using swine (unpublished data). From this study, we have histologically confirmed the safety of compression of AVP II. In all CAE patients of our series, AVP IIs were adapted to LSA embolization by compression. CAE could provide effective LSA embolization without any complications on TEVAR combined with or without debranching bypass. Although, a larger-sized introducer sheath is necessary to deliver the AVP II, no significant differences in complication rate were observed between CAE and CCE.
The cost of embolization devices such as Amplatzer vascular plugs and standard coils have been reviewed by several investigators. American investigators found that the Amplatzer vascular plug was 69% less expensive based on the cost of the coils or plug alone in transluminal hypogastric artery occlusion during abdominal endovascular aortic repair. 17 In the series by Vandy et al., 17 7 .53 coils were utilized compared with 1.35 plugs. European investigators found that the Amplatzer plug was 71% less expensive based on the cost of the devices alone for occlusion of the internal iliac artery. 19 In our series, 10.2 coils were placed compared with only one plug. As such, the CAE cost 80% less than the CCE, corroborating findings from those reports. As such, CAE can reduce the cost of embolization devices.
Being a retrospective study, the present study has several limitations including lack of randomization. In addition, the sample size is relatively small, especially in the CCE group. First, although no major stroke was seen in this study, we did not evaluate the incidence of subclinical cerebral infarction during the embolization procedure. Further examination is required with regard to the incidence of micro cerebral embolism. Second, the procedure time of CCE or CAE could not be compared because it was not recorded, while the whole procedure time of TEVAR was recorded. Third, the pressure on the vessel wall by compressing method was not evaluated.
In the present study, we retrospectively reviewed success rate and safety of CAE and compared with CCE. We designed the CAE for prevention of type II endoleaks associated with TEVAR for distal arch pathology. CAE was found to be safe and effective for LSA proximal embolization. CAE can reduce the cost of embolization devices and as such, CAE could be a candidate to supplant CCE.
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